NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA diagnostic technologies, today announced that two of its pending patent applications have been published by the United States Patent and Trade Office (USPTO). The two applications are directed at methods to diagnose and monitor infectious diseases, such as viruses and bacteria, by detecting their transrenal DNA signature sequences in urine, even though the infection is outside the urinary tract and not detectable by traditional means such as cell cultures. The method provides a way to conduct non-invasive tests on patients well before the onset of more overt symptoms.
Results of a clinical study on tuberculosis had been presented to medical researchers in Paris at the 36th Union World Conference on Lung Health co-sponsored by the United States Centers for Disease Control and Prevention.
“We are continuing to develop the transrenal DNA diagnostics and expand the range of applications to include infectious diseases caused by a variety of agents,” said Dr. L. David Tomei, CEO of Xenomics. “Our long term goal is to provide a simple, safe, and highly sensitive means of detecting diseases using basic urine specimens.”
Typically, United States patent applications take approximately three years to be examined and issued, with the exclusivity period beginning on the date of filing the application. In addition to these US applications, the company has filed corresponding applications in the World Intellectual Property Organization, in order to secure worldwide rights to the inventions.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company’s prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive “Lazarus Spallanzani”) in Rome, in the form of a research and development company called SpaXen Italia, S.R.L. For additional information, please visit http://www.xenomics.com. Xenomics’ stock trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as “expect,” “might,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics’ Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics’ technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact: Xenomics, Inc. L. David Tomei 212-297-0808 ldtomei@xenomics.com
Source: Xenomics, Inc.
